Aberrations in Carnitine Homeostasis in Congenital Heart Disease With Increased Pulmonary Blood Flow (L-carn)
|ClinicalTrials.gov Identifier: NCT01825369|
Recruitment Status : Unknown
Verified January 2015 by University of California, San Francisco.
Recruitment status was: Recruiting
First Posted : April 5, 2013
Last Update Posted : January 13, 2015
Infants with congenital heart disease and increased pulmonary blood flow have altered carnitine homeostasis that is associated with clinical outcomes; and L-carnitine treatment will attenuate these alterations and improve clinical outcomes.
The investigators will pilot a trial assessing the safety and pharmacokinetics of perioperative IV L-carnitine administration in these patients. To this end, a pilot clinical trial is proposed. Infants with ventricular septal defects or atrioventricular septal defects undergoing complete surgical repair will receive L-carnitine (25, 50, or 100 mg/kg, IV) just prior to cardiopulmonary bypass (CPB) and 2hr after CPB. Carnitine levels will be measured before CPB, and before and 0.5, 1.5, 3, 5, 9, 12, and 24h after the second dose. The safety, pharmacokinetic profile, feasibility, and effect of L-carnitine administration on biochemical parameters, as well as clinical outcomes will be determined. The investigators expect this pilot to provide the data needed to proceed with a placebo-based randomized, controlled, trial.
|Condition or disease||Intervention/treatment||Phase|
|Heart Septal Defects, Ventricular Atrioventricular Septal Defect||Drug: IV L-carnitine||Phase 1|
AIM: To pilot a trial assessing the safety and pharmacokinetics (PK) of perioperative IV L-carnitine administration in these patients. To this end, a pilot clinical trial is proposed. Infants with VSD or AVSD undergoing complete repair will receive L-carnitine, in one of 3 doses (25, 50, or 100 mg/kg, IV), just prior to CPB, and again 2 hr after CPB. Serial blood samples will be obtained to determine free, total, and acylcarnitine levels, and plasma markers of mitochondrial function, oxidative stress, and bioavailable NO. Adverse events will be sought, and clinical outcomes will be assessed.
Study design: The inclusion and exclusion criteria are as described in Aim 3A except only infants with VSD or AVSD will be enrolled (no TOF). The safety profile of L-carnitine is outstanding, with no reports of toxicity from overdose reported113. In fact, the only adverse reactions reported are transient nausea and vomiting, and less commonly gastritis. However, although rare, seizures have been reported to occur in patients receiving L-carnitine. Therefore, the major adverse events that will be monitored include evidence of seizure activity and GI bleeding. As per routine, any patient suspected of having seizures is monitored with continuous EEG. Dosing is not well studied in children, particularly critically ill children67, 114-116117. In addition, the effect of CPB on L-carnitine clearance in children is not known. Therefore, a major goal of this sub-aim is to establish a pharmacokinetic profile of L-carnitine in this patient population undergoing surgery with CPB, in order to move forward with a larger randomized trial powered for efficacy in prevention of increased PVR post-bypass in at-risk infants. Plasma concentration profiles after IV bolus dosing in adults were described by a two-compartmental model67, 113, 114, 118. Usual pediatric dosing is not well delineated, but recommendations include a 50 mg/kg bolus followed by an infusion of 50mg/kg/day, that can be increased to 300 mg/kg/day113, 119. Therefore, we will begin at a lower dose (25 mg/kg), and escalate the dose after each group of 5. No intra-patient escalation will be allowed and the dose will not be escalated until all patients in the current dose level have been followed to hospital discharge or 30 days post-op and the safety and PK data have been analyzed. The DSMB will approve all dose escalations. The dosing goal will be to achieve normal or supra-normal free carnitine levels (~50 μmol/L) and low AC levels (~3 μmol/L) just before and for 24 hrs after CPB; the period with the greatest risk of pulmonary vascular morbidity.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||15 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase 1 Study of the Safety and Pharmacokinetics of Perioperative IV L-carnitine Administration in Patients With Congenital Heart Disease With Increased Pulmonary Blood Flow|
|Study Start Date :||December 2014|
|Estimated Primary Completion Date :||July 2015|
|Estimated Study Completion Date :||July 2015|
Experimental: IV L-carnitine
L-carnitine (25, 50, or 100mg/kg IV) will be given, 30-60 minutes prior to the initiation of CPB, and a second dose ~2 hr. following separation from CPB (with a minimum of 4 hrs from initial dose). The first 5 subjects will receive 25 mg/kg, with an escalation of dose after each 5 subjects enrolled. The study drug will be brought to the operating room and administered over 5 minutes by the anesthesiologist after an IV has been placed. Prior to the administration of the study drug, and again 24 and 48 hrs after CPB, 3.0 ml of blood will be collected for determinations of carnitine levels (free, total, and acylcarnitine), mitochondrial function, ROS and bioavailable NO as described in Aim 3A. Additional blood (0.5-1.0 ml) will be obtained to determine carnitine levels before CPB, and then before and 0.5, 1.5, 3, 5, 9, 12, and 24h after the second dose.
Drug: IV L-carnitine
See arm description
- Blood carnitine level (free, total, and acylcarnitine) [ Time Frame: At enrollment (first dose), and again 24 and 48 hrs after enrollment. 2 hours after enrollment (at time of second dose) and 0.5, 1.5, 3, 5, 9, 12, and 24h after the second dose. ]
- Bioavailable nitric oxide [ Time Frame: At enrollment (first dose), and again 24 and 48 hrs after enrollment. ]
- Plasma levels of superoxide [ Time Frame: At enrollment (first dose), and again 24 and 48 hrs after enrollment. ]
- Carnitine Palmityl Transporter-1 and -2 expression [ Time Frame: At enrollment (first dose), and again 24 and 48 hrs after enrollment. ]
- Cardiopulmonary bypass [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 2 weeks ]
- Echocardiographic measurements [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 2 weeks ]Estimates of PPA and right ventricular (RV) function by transesophageal ECHO (TEE)
- Blood BNP level [ Time Frame: Daily during the hospitalization, estimated to be an average of 2 weeks ]
- Duration of mechanical ventilation [ Time Frame: During hospitalization which is an average of 2 weeks ]
- Vasopressor infusions [ Time Frame: Duration of hospitalization which is an average of 2 weeks ]
- Need for inhaled nitric oxide [ Time Frame: During hospitalization (average of 2 weeks) ]
- Incidence of low cardiac output syndrome [ Time Frame: Postoperative hospitalization (average of 2 weeks) ]
- Need for extracorporeal life support [ Time Frame: During hospitalization (average of 2 weeks) ]
- Plasma H202 levels [ Time Frame: At enrollment (first dose), and again 24 and 48 hrs after enrollment. ]
- Aortic cross clamp times [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 2 weeks ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01825369
|Contact: Jeffrey Fineman, MDfirstname.lastname@example.org|
|Contact: Monique R Radman, MD||415-502-6390||RadmanM@peds.ucsf.edu|
|United States, California|
|University of California San Francisco||Recruiting|
|San Francisco, California, United States, 94143-0106|
|Contact: Jeffrey Fineman, MD 415-502-6390 email@example.com|
|Contact: Monique R Radman, MD 415-502-6390 RadmanM@peds.ucsf.edu|
|Principal Investigator:||Jeffrey Fineman, MD||University of California, San Francisco|